Record setting snow storm wrecked havoc on everyone's life, and I found myself trapped inside this place until I managed to push the door open. Snow shoveling is hard work, after three days, I am still seeing the reminescene of memorable sunday.
I could honestly say that I am probably the only fool brave (or stupid) enough to pick up flowers on stormy sunday and deliver it to my dear.
Too bad, that midterm pretty much ruined any possibility of spending some quality time on Valentine's Day: (Status Report Time!)
School:
One midterm done, and the other will be here soon.
Well-being:
WFWN
Job:
No change, same old, same old.
Scanlation:
Nothing at the moment, but trying to find a group to work on Hanamizawa Q-taro's "Momoiro Sango".
Reading:
Book: Wicked (Fiction/Fantasy/Drama), American Vertigo (Non-Fiction)
Manga: Toshiue no Hito (Seinen/Ecchi/Drama/Romance)
Chokotto Sister (Seinen/Ecchi/Drama/Comedy/Romance)
Lucu Lucu (Shonen/Comedy/Occult)
Watching:
2006 Torino 20th Winter Olympic (Apollo Anton Ohno stinks... Booo~)
Anime: Mai-Otome (Shonen/Action/Fantasy)
Fate/Stay Night (Shonen/Action/Fantasy)
Kashimashi ~Girl Meets Girl~ (Shoujo-Yuri/School/Drama/Romance)
Games:
Shin Megami Tensei (True Goddess Reborn): Nocturne
Two cents:
Two companies you should carefully follow this year: Pfizer, and Merck.
Pfizer is losing patent on Zoloft, a popular anti-depressant medicine, but will release the inhalation form of human insulin (Exubera), first of its kind this year. If Exubera proves to be a hit, their stock will go up... (up to 40% is my guess). However, if it proves to be a failure (due to complication of COPD, and low-tolerance towards frail and elderly patients), then Pfizer will struggle this year.
Merck is losing patent on Zocor, once popular cholesterol reduction drug ("Statin" family-lost some popularity after Pfizer's Lipitor, and AstraZeneca's Crestor came out). However, their success will be based on newly approved HPV Vaccine which may reduce the risk of women getting cervical cancer in their later years.
Enough chatter, and new review will be here soon.
